Characterization of an Unknown Impurity in Glucosamine Sulfate Sodium Chloride by HPLC-Q-TOF MS and NMR
-
Published:2019-07-18
Issue:6
Volume:15
Page:650-660
-
ISSN:1573-4129
-
Container-title:Current Pharmaceutical Analysis
-
language:en
-
Short-container-title:CPA
Author:
Zhang Miao1, Zhu Peixi2, Chen Yue3, Ni Weifang3, Li Yu3, Hong Liya3
Affiliation:
1. College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, 310014, China 2. College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China 3. Zhejiang Institute for Food and Drug Control, Hangzhou, 310052, China
Abstract
Background:
Glucosamine sulfate sodium chloride (glucosamine-SP) is mainly used for the
treatment of osteoarthritis. During quality control of glucosamine-SP capsules, an unknown impurity
was detected. Another unknown degradation product was generated together with above-mentioned
impurity in heat condition.
Objective:
The study aimed to characterize an unknown impurity in glucosamine-SP capsules.
Methods:
A new volatile HPLC method compatible with mass spectrometry detection was set up. An
amino column at 35 °C with a mobile phase consisting of water and acetonitrile (20: 80, v/v) was used
at a flow rate of 1.5 ml/min at 297 nm. High-performance liquid chromatography quadrupole time-offlight
mass spectrometry (HPLC-Q-TOF MS) was used to identify the impurity with the electrospray
ionization (ESI) source in the positive ionization mode.
Results:
The results of HPLC-Q-TOF MS analysis indicated that the protonated molecule ions [M + H]+
of the unknown impurity and the novel degradation product were both at m/z 287. Preparative LC method
was put into practice with a Prep-C18 column with a mobile phase consisting of water and acetonitrile
(99: 1, v/v) at a flow rate of 20.0 ml/min at 297 nm. The assignment of the 1D and 2D NMR signals
was performed for the unknown impurity. In addition, the formation of impurities was also studied.
Conclusion:
An unknown impurity and a degradation product in glucosamine-SP capsules were characterized.
They were assigned as (1R, 2S, 3R)-1-(5-((S, E)-3, 4-dihydroxybut-1-en-1-yl) pyrazin-2-yl)
butane-1, 2, 3, 4-tetraol and (1R, 2S, 3R)-1-(5-((S, Z)-3, 4-dihydroxybut-1-en-1-yl) pyrazin-2-yl) butane-
1, 2, 3, 4-tetraol.
Funder
Research Project of China food and drug science and technology project of Zhejiang Food and Drug Administration in 2018
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Molecular Medicine,Biochemistry,Biophysics
Reference20 articles.
1. Byron DH. European Patent, EP 0 444 000 A2, February 12, Storage-stable glucosamine sulphate oral dosage
forms and methods for their manufacture,, 1991, 107,, 151-, 2. . European Pharmacopeia, ,, 2016, 107,, 151-, 3. Yu X, Wang F, Li J, Shan W, Zhu B, Wang J. J Pharm Biomed Anal, Separation and characterization of unknown impurities and isomers in flomoxef sodium by LC-IT-TOF MS and study of their negative-ion fragmentation regularities.,, 2017, 140,, 81-90, 4. Wang J, Xu Y, Wen C, Wang Z. Anal Chim Acta, Application of a trap-free two-dimensional liquid chromatography combined with ion trap/time-of-flight mass spectrometry for separation and characterization of impurities and isomers in cefpiramide.,, 2017, 992,, 42-54, 5. Ramachandra B. Crit Rev Anal Chem, Development of impurity profiling methods using modern analytical techniques.,, 2017, 47,, 13-,
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|